Skip to content

Syndax Pharmaceuticals, Inc.

SNDX

CIK 0001395937

← back to feed
Revenue (TTM)
$168.74M
+627.8% YoY Q1 Apr 2026
Net Income (TTM)
−$260.08M
+10.5% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$2.99
+11.6% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
-145.0%
Q1 Apr 2026
Net Margin
-154.1%
Q1 Apr 2026
Free Cash Flow (TTM)
−$268.47M
Q1 Apr 2026
Cash
$130.89M
Q1 Apr 2026
Total Debt
$343.97M
Q1 Apr 2026
Shares Outstanding
88.61M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings